286 related articles for article (PubMed ID: 31264434)
21. Genitourinary cancer predisposition syndromes.
Gallagher DJ; Feifer A; Coleman JA
Hematol Oncol Clin North Am; 2010 Oct; 24(5):861-83. PubMed ID: 20816578
[TBL] [Abstract][Full Text] [Related]
22. Spectrum of genomic alterations in FGFR3: current appraisal of the potential role of FGFR3 in advanced urothelial carcinoma.
Sethakorn N; O'Donnell PH
BJU Int; 2016 Nov; 118(5):681-691. PubMed ID: 27271022
[TBL] [Abstract][Full Text] [Related]
23. Inherited urologic malignant disorders: nursing implications.
Middelton L; Lessick M
Urol Nurs; 2003 Feb; 23(1):15-8, 23-9; quiz 30. PubMed ID: 12677717
[TBL] [Abstract][Full Text] [Related]
24. Emerging critical role of molecular testing in diagnostic genitourinary pathology.
Netto GJ; Cheng L
Arch Pathol Lab Med; 2012 Apr; 136(4):372-90. PubMed ID: 22458900
[TBL] [Abstract][Full Text] [Related]
25. MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors.
Jardim DL; de Melo Gagliato D; Falchook G; Zinner R; Wheler JJ; Janku F; Subbiah V; Piha-Paul SA; Fu S; Tannir N; Corn P; Tang C; Hess K; Roy-Chowdhuri S; Kurzrock R; Meric-Bernstam F; Hong DS
Clin Genitourin Cancer; 2015 Feb; 13(1):e19-26. PubMed ID: 25087088
[TBL] [Abstract][Full Text] [Related]
26. Emerging therapeutic agents for genitourinary cancers.
Zarrabi K; Paroya A; Wu S
J Hematol Oncol; 2019 Sep; 12(1):89. PubMed ID: 31484560
[TBL] [Abstract][Full Text] [Related]
27. Circadian chemotherapy for gynecological and genitourinary cancers.
Kobayashi M; Wood PA; Hrushesky WJ
Chronobiol Int; 2002 Jan; 19(1):237-51. PubMed ID: 11962679
[TBL] [Abstract][Full Text] [Related]
28. Immunotherapy in genitourinary malignancies.
Wattenberg MM; Fong L; Madan RA; Gulley JL
Curr Opin Urol; 2016 Nov; 26(6):501-7. PubMed ID: 27471994
[TBL] [Abstract][Full Text] [Related]
29. Biologic tools to personalize treatment in genitourinary cancers.
Bracarda S; Sisani M; Del Buono S; Ishiwa O; Montagnani F;
Crit Rev Oncol Hematol; 2012 Dec; 84 Suppl 1():e42-8. PubMed ID: 21232974
[TBL] [Abstract][Full Text] [Related]
30. Long non-coding RNAs in genitourinary malignancies: a whole new world.
Flippot R; Beinse G; Boilève A; Vibert J; Malouf GG
Nat Rev Urol; 2019 Aug; 16(8):484-504. PubMed ID: 31110275
[TBL] [Abstract][Full Text] [Related]
31. Pediatric genitourinary tumors.
McLean TW; Castellino SM
Curr Opin Oncol; 2008 May; 20(3):315-20. PubMed ID: 18391632
[TBL] [Abstract][Full Text] [Related]
32. Inside prostate cancer news from the 2021 ASCO Genitourinary Cancers Symposium.
Iacovelli R; Astore S; Ciccarese C; Cannella MA; Bove P; Iacovelli V; Tortora G
Expert Rev Anticancer Ther; 2021 Nov; 21(11):1207-1210. PubMed ID: 34493147
[TBL] [Abstract][Full Text] [Related]
33. Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma.
Bagrodia A; Cha EK; Sfakianos JP; Zabor EC; Bochner BH; Al-Ahmadie HA; Solit DB; Coleman JA; Iyer G; Scott SN; Shah R; Ostrovnaya I; Lee B; Desai NB; Ren Q; Rosenberg JE; Dalbagni G; Bajorin DF; Reuter VE; Berger MF;
J Urol; 2016 Jun; 195(6):1684-1689. PubMed ID: 26778714
[TBL] [Abstract][Full Text] [Related]
34. Gene and immune-based therapies for genitourinary malignancies: current status and future prospects.
Zisman A; Pantuck AJ; Belldegrun A
Isr Med Assoc J; 2000 Jan; 2(1):33-42. PubMed ID: 10892369
[No Abstract] [Full Text] [Related]
35. Bisphosphonate anticancer activity in prostate cancer and other genitourinary cancers.
Saad F; Mulders P
Anticancer Agents Med Chem; 2012 Feb; 12(2):129-36. PubMed ID: 21864229
[TBL] [Abstract][Full Text] [Related]
36. A Genitourinary Cancer-specific Scoring System for the Prediction of Survival in Patients with Bone Metastasis: A Retrospective Analysis of Prostate Cancer, Renal Cell Carcinoma, and Urothelial Carcinoma.
Owari T; Miyake M; Nakai Y; Morizawa Y; Hori S; Anai S; Tanaka N; Fujimoto K
Anticancer Res; 2018 May; 38(5):3097-3103. PubMed ID: 29715146
[TBL] [Abstract][Full Text] [Related]
37. The biological complexity of urothelial carcinoma: Insights into carcinogenesis, targets and biomarkers of response to therapeutic approaches.
Grivas PD; Melas M; Papavassiliou AG
Semin Cancer Biol; 2015 Dec; 35():125-32. PubMed ID: 26304731
[TBL] [Abstract][Full Text] [Related]
38. Genitourinary Tumors: Update on Molecular Biomarkers for Diagnosis, Prognosis and Prediction of Response to Therapy.
Cimadamore A; Scarpelli M; Santoni M; Massari F; Tartari F; Cerqueti R; Lopez-Beltran A; Cheng L; Montironi R
Curr Drug Metab; 2019; 20(4):305-312. PubMed ID: 30799789
[TBL] [Abstract][Full Text] [Related]
39. Beyond conventional chemotherapy: Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma.
Ikeda S; Hansel DE; Kurzrock R
Cancer Treat Rev; 2015 Sep; 41(8):699-706. PubMed ID: 26138514
[TBL] [Abstract][Full Text] [Related]
40. Erdafitinib to treat urothelial carcinoma.
Hanna KS
Drugs Today (Barc); 2019 Aug; 55(8):495-501. PubMed ID: 31461086
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
